6533b82efe1ef96bd12930c1
RESEARCH PRODUCT
Pneumococcal conjugate vaccines: proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
Ron DaganBeverly M. GainesStephen I. PeltonKatherine L. O'brienKeith P. KlugmanDagna LauferHeinz J. Schmittsubject
Potential impactChemotherapymedicine.medical_specialtyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industrymedicine.medical_treatmentPublic Health Environmental and Occupational HealthAntimicrobialmedicine.disease_causeClinical trialInfectious DiseasesPneumococcal vaccineImmunizationStreptococcus pneumoniaeImmunologyMolecular MedicineMedicinebusinessIntensive care medicineConjugatedescription
Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the effect of pneumococcal conjugate vaccines on replacement disease and the rate of resistance among replacement serotypes; (5) the current recommendations for the use of PNCRM7; and (6) the potential impact of conjugate vaccines in Europe and the Asia-Pacific region.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-04-02 | Vaccine |